Konstantia-maria Chavele
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.
Journal: Research and practice in thrombosis and haemostasis
Published: October 02, 2025
Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: April 04, 2025
Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial.
Journal: Therapeutic advances in hematology
Published: May 10, 2024
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Journal: The New England journal of medicine
Published: February 22, 2023
Spatiotemporal segregation of human marginal zone and memory B cell populations in lymphoid tissue.
Journal: Nature communications
Published: April 16, 2018
Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: February 15, 2015
B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis.
Journal: Annals of the rheumatic diseases
Published: November 20, 2013
Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis.
Journal: Kidney international
Published: February 21, 2013
B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.
Journal: Rheumatology (Oxford, England)
Published: February 17, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026